{
  "cik": 2007919,
  "cik_padded": "0002007919",
  "entityName": "Inhibrx Biosciences, Inc.",
  "fiscal_years": [
    {
      "accn": "0002007919-26-000006",
      "filed": "2026-03-19",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 31000.0,
        "cash": 124220000.0,
        "eps_diluted": -9.04,
        "free_cash_flow": -129825000.0,
        "net_income": -140055000.0,
        "operating_cash_flow": -129794000.0,
        "operating_income": -135025000.0,
        "revenue": 1300000.0,
        "stockholders_equity": 7993000.0,
        "total_assets": 146478000.0,
        "total_liabilities": 138485000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "leverage": 17.32578506192919,
        "roa_avg2y": -0.8559641858546349,
        "roa_period_end": -0.9561504116659159,
        "roe_avg2y": -1.9784993325187001
      }
    },
    {
      "accn": "0002007919-26-000006",
      "filed": "2026-03-19",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 2597000.0,
        "cash": 152596000.0,
        "eps_diluted": 112.62,
        "free_cash_flow": -197006000.0,
        "net_income": 1687572000.0,
        "operating_cash_flow": -194409000.0,
        "operating_income": -331448000.0,
        "stockholders_equity": 133584000.0,
        "total_assets": 180767000.0,
        "total_liabilities": 47183000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "leverage": 0.3532084680800096,
        "roa_avg2y": 6.906937338845005,
        "roe_avg2y": 19.059242067458367
      }
    },
    {
      "accn": "0002007919-26-000006",
      "filed": "2026-03-19",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "revenue": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 4593000.0,
        "cash": 277924000.0,
        "eps_diluted": -20.48,
        "free_cash_flow": -197902000.0,
        "net_income": -241361000.0,
        "operating_cash_flow": -193309000.0,
        "operating_income": -219221000.0,
        "revenue": 1800000.0,
        "stockholders_equity": 43503000.0,
        "total_assets": 307893000.0,
        "total_liabilities": 264390000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "leverage": 6.0775118957313286,
        "roa_period_end": -0.7839119434348946,
        "roe_avg2y": -4.753072075620323
      }
    },
    {
      "accn": "0002007919-25-000019",
      "filed": "2025-03-17",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": 58057000.0
      },
      "period_end": "2022-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0002007919-26-000006",
    "filed": "2026-03-19",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2836",
  "sic_description": "Biological Products, (No Diagnostic Substances)",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0002007919.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0002007919.json"
  },
  "ticker": "INBX"
}